Reneo Q2 net loss $12.3M; positive LC-FAOD results; STRIDE enrollment two-thirds

OnKure Therapeutics, Inc.

2022-Q2 EPS reported -$1.04

Net loss $12.3M ($0.50/share) vs $9.2M ($0.43/share) in Q2 2021.
Cash, cash equivalents, and short-term investments ~$127M as of June 30, 2022.
R&D expenses $8.1M (up $1.8M YoY); G&A $4.3M (up $1.4M).
Positive results from REN001 Phase 1b LC-FAOD study; plan to meet regulators.
STRIDE pivotal PMM study enrollment two-thirds complete; on track for year-end 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.